image credit- shutterstock
Verified Clinical Trials (VCT), the global leader in clinical trial subject registry solutions, has officially launched operations in Japan through a collaboration with Medical Revolutions Japan (MRJ) and the Japan Association of Contract Institutes for Clinical Pharmacology (JACIC) to address the growing global challenge of duplicate and professional research subjects in clinical trials.
For the past thirty years, Japan’s only system for preventing duplicate subject registration was developed by JACIC and used across Phase 1 studies. However, a recent review concluded that the system requires substantial modernisation to meet international standards and support the growing number of global clinical trials. In addition, duplicate subjects in clinical trials have become a growing concern in Phase II and Phase III trials as well.
After extensive evaluation, the VCT platform, widely adopted as the global standard, was selected as the best solution and replacement.
With the support of MRJ, which was commissioned by JACIC to assist with domestic implementation, Verified Clinical Trials has begun initiating sites in Japan, with additional sites expected to join in the coming weeks and months. These sites will benefit from the biometric capabilities of the VCT system, offering a higher level of subject authentication and protocol compliance. This rollout will include sites conducting Phase I through Phase IV clinical trials.
Verified Clinical Trials brings to Japan a cross-sponsor, cross-therapeutic area subject registry already in use in up to 40 countries. The platform not only detects but also prevents duplicate subjects and other protocol violations at the time of screening, and maintains protections throughout the entire duration of the trial.
